The latest results of clinical trials utilizing a personalized cellular therapy developed by a team from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania were presented during the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The new results – from trials for patients with advanced lymphoma, multiple myeloma, and pancreatic cancer – expand on Penn’s work with chimeric antigen receptor (CAR) therapies.
Read the Department of Communications news release.

Explanatory video on the Chimeric Antigen Receptor (CAR) therapy research: